Shares of biotechnology company United Therapeutics (NASDAQ:UTHR) fell 10.9% in the afternoon session after the company reported disappointing fourth-quarter results: EPS missed analysts ...
Hosted on MSN27d
United Therapeutics Stock Down Despite Q4 Earnings & Sales BeatUnited Therapeutics’ UTHR fourth-quarter 2024 earnings of $6.19 per share beat the Zacks Consensus Estimate of $6.10. Earnings rose 42% year over year on the back of higher product sales.
United Therapeutics is highly undervalued with a P/E of 16x and EV/EBITDA of 8.64x, compared to sector medians of 28x and 15.15x, respectively. The company shows strong revenue growth, driven by ...
Biotechnology company United Therapeutics (NASDAQ:UTHR) will be reporting earnings tomorrow before market open. Here’s what investors should know. United Therapeutics beat analysts’ revenue ...
UNITED THERAPEUTICS ($UTHR) is expected to release its quarterly earnings data on Wednesday, February 26th before market open, per Finnhub. Analysts are expecting ...
United Therapeutics (UTHR) reported $735.9 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 19.7%. EPS of $6.19 for the same period compares to $4. ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback